香溪河流域梯级水库底栖动物群落比较

对香溪河流域3座梯级水库(古洞口一级水库、古洞口二级水库和三峡水库香溪河库湾)的底栖动物进行了比较生态学研究。运用主成分分析(PCA)对梯级水库的水质进行研究,表明沿着水库的梯度水质逐渐恶化。运用非度量多维标度法(NMS)对梯级水库的底栖动物群落结构进行相似性比较,表明选择水库湖泊区的样点进行梯级水库底栖动物生态学研究具有典型代表性。在物种组成和密度方面,古洞口一级水库和香溪河库湾都是寡毛类占优势,古洞口二级水库是摇蚊幼虫占优势。但3个水库都是耐污种占优势。采用典型对应分析(CCA)解析底栖动物群落结构

香溪河流域梯级水库底栖动物群落比较

对香溪河流域3座梯级水库（古洞口一级水库、古洞口二级水库和三峡水库香溪河库湾）的底栖动物进行了比较生态学研究。运用主成分分析（PCA）对梯级水库的水质进行研究，表明沿着水库的梯度水质逐渐恶化。运用非度量多维标度法（NMS）对梯级水库的底栖动物群落结构进行相似性比较，表明选择水库湖泊区的样点进行梯级水库底栖动物生态学研究具有典型代表性。在物种组成和密度方面，古洞口一级水库和香溪河库湾都是寡毛类占优势，古洞口二级水库是摇蚊幼虫占优势。但3个水库都是耐污种占优势。采用典型对应分析（CCA）解析底栖动物群落结构与环境因子的关系，显示3个水库群落结构的差异主要由浊度造成。用TOC／Turb来表征有机物对浊度的贡献，结果显示古洞口二级水库有机物对浊度的贡献相对较小，因而表明泥沙等无机物对浊度的贡献相对较大

温带阔叶红松林生态系统潜热通量模拟——气孔导度组合模型在Shuttleworth-Wallace双源模型中的应用(英文)

叶片水平的气孔导度组合模型已被成功扩展到冠层水平,并被应用于冬小麦生态系统潜热通量的模拟研究,但该研究仅基于1a的数据,有必要研究模型在更长时间尺度和其它生态系统类型的适用性。以长白山阔叶红松林(CBS)为研究对象,将组合模型进一步应用于Shuttleworth-Wallace双源模型,模拟了CBS3a生长季内的潜热通量,利用涡度相关系统观测的潜热通量数据对模型进行验证,并对比了双源模型与单源模型的模拟结果。结果显示,双源模型较单源模型能取得更高的模拟精度,生长季不同时期的潜热通量模拟值和实测值的日变化较一致。对双源模型模拟值和实测潜热通量的相关分析显示,二者直线回归斜率和R2分别为0.96和0.72。对长白山阔叶红松林生态系统的蒸散和植被蒸腾的季节和年际变异分析发现,影响冠层蒸散和植被蒸腾季节动态的主要因素是饱和差和辐射,而影响它们年际动态的主要因素则是饱和差和温度

温带阔叶红松林生态系统潜热通量模拟:气孔导度组合模型在Shuttleworth-Wallace双源模型中的应用(英文)

叶片水平的气孔导度组合模型已被成功扩展到冠层水平,并被应用于冬小麦生态系统潜热通量的模拟研究,但该研究仅基于1a的数据,有必要研究模型在更长时间尺度和其它生态系统类型的适用性。以长白山阔叶红松林(CBS)为研究对象,将组合模型进一步应用于Shuttleworth-Wallace双源模型,模拟了CBS3a生长季内的潜热通量,利用涡度相关系统观测的潜热通量数据对模型进行验证,并对比了双源模型与单源模型的模拟结果。结果显示,双源模型较单源模型能取得更高的模拟精度,生长季不同时期的潜热通量模拟值和实测值的日变化较中国科学院知识创新工程重要方向资助项目(KZCX2-YW-432);国家自然科学重大资助项目(30590381)~

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel